{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:37:16Z","timestamp":1784961436259,"version":"3.55.0"},"reference-count":12,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>A new International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)<\/jats:italic> diagnosis code (U09.9 Post COVID-19 condition, unspecified) was introduced by the Centers for Disease Control and Prevention on October 1, 2021.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine the use of the U09.9 code and describe concurrently diagnosed conditions to understand physician use of this code in clinical practice.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study of US patients with an ICD-10-CM<\/jats:italic> code for post\u2013COVID-19 condition used deidentified patient-level claims data aggregated by HealthVerity. Children and adolescents (aged 0-17 years) and adults (aged 18-64 and \u226565 years) with a post\u2013COVID-19 condition code were identified between October 1, 2021, and January 31, 2022. To identify a prior COVID-19 diagnosis, 3 months of continuous enrollment (CE) before the post\u2013COVID-19 diagnosis date was required.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Presence of the ICD-10-CM<\/jats:italic> U09.9 code.<\/jats:p><\/jats:sec>Results<\/jats:title>There were 56\u202f143 patients (7723 female patients [61.2%]; mean [SD] age, 47.6 [19.2] years) with a post\u2013COVID-19 diagnosis code, with cases increasing in mid-December 2021 following the trajectory of the Omicron case wave by 3 to 4 weeks. The analysis cohort included 12\u202f622 patients after the 3-month preindex CE criteria was applied. Among this cohort, the median (IQR) age was 49 (35-61) years; however, 1080 (8.6%) were pediatric patients. The U09.9 code was used most often in the outpatient setting, although 305 older adults (14.0%) were inpatients. Only 698 patients (5.5%) had at least 1 of the 5 codes listed as possible concurrent conditions in the coding guidance. Only 8879 patients (70.4%) had a documented acute COVID-19 diagnosis code (569 [52.7%] among children), and the median (IQR) time between acute COVID-19 and post\u2013COVID-19 diagnosis codes was 56 (21-200) days. The most common concurrently coded conditions varied by age; children experienced COVID-19\u2013like symptoms (eg, 207 [19.2%] had cough and 115 [10.6%] had breathing abnormalities), while 459 older adults aged 65 years or older (21.1%) experienced respiratory failure and 189 (8.7%) experienced viral pneumonia.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This retrospective cohort study found patients with a post\u2013COVID-19 ICD-10-CM<\/jats:italic> diagnosis code following the acute phase of COVID-19 disease among patients of all ages in clinical practice in the US. The use of the U09.9 code encompassed a wide range of conditions. It will be important to monitor how the use of this code changes as the pandemic continues to evolve.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.35089","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T15:40:12Z","timestamp":1665070812000},"page":"e2235089","source":"Crossref","is-referenced-by-count":35,"title":["Use of the Postacute Sequelae of COVID-19 Diagnosis Code in Routine Clinical Practice in the US"],"prefix":"10.1001","volume":"5","author":[{"given":"Leah J.","family":"McGrath","sequence":"first","affiliation":[{"name":"Real World Evidence Center of Excellence, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie M.","family":"Scott","sequence":"additional","affiliation":[{"name":"Real World Evidence Center of Excellence, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Surinach","sequence":"additional","affiliation":[{"name":"Genesis Research, Hoboken, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Chambers","sequence":"additional","affiliation":[{"name":"Global Product Development Statistics, Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Benigno","sequence":"additional","affiliation":[{"name":"Real World Evidence Center of Excellence, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Real World Evidence Center of Excellence, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"issue":"1","key":"zoi221000r1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36142","article-title":"Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge.","volume":"4","author":"Bellan","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi221000r2","doi-asserted-by":"publisher","first-page":"n1648","DOI":"10.1136\/bmj.n1648","article-title":"Long covid\u2014mechanisms, risk factors, and management.","volume":"374","author":"Crook","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"zoi221000r4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","article-title":"Post-acute COVID-19 syndrome.","volume":"27","author":"Nalbandian","year":"2021","journal-title":"Nat Med"},{"issue":"24","key":"zoi221000r6","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1001\/jama.2020.20323","article-title":"Uptake and accuracy of the diagnosis code for COVID-19 among US hospitalizations.","volume":"324","author":"Kadri","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"zoi221000r8","doi-asserted-by":"publisher","first-page":"6571","DOI":"10.1038\/s41467-021-26513-3","article-title":"Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status.","volume":"12","author":"Xie","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"zoi221000r9","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1016\/S2352-4642(21)00124-3","article-title":"Post-acute COVID-19 outcomes in children with mild and asymptomatic disease.","volume":"5","author":"Say","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"zoi221000r10","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s00431-021-04345-z","article-title":"Long COVID symptoms and duration in SARS-CoV-2 positive children\u2014a nationwide cohort study.","volume":"181","author":"Borch","year":"2022","journal-title":"Eur J Pediatr"},{"issue":"7","key":"zoi221000r11","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1111\/apa.v110.7","article-title":"Preliminary evidence on long COVID in children.","volume":"110","author":"Buonsenso","year":"2021","journal-title":"Acta Paediatr"},{"issue":"6","key":"zoi221000r12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1017\/ice.2020.1273","article-title":"Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): review of current literature.","volume":"42","author":"Fontana","year":"2021","journal-title":"Infect Control Hosp Epidemiol"},{"key":"zoi221000r3","doi-asserted-by":"crossref","unstructured":"Tabacof? L, Tosto-Mancuso? J, Wood? J, . Post-acute COVID-19 syndrome negatively impacts health and wellbeing despite less severe acute infection.? MedRxiv. Preprint posted online November 6, 2020. doi:10.1101\/2020.11.04.20226126","DOI":"10.1101\/2020.11.04.20226126"},{"key":"zoi221000r5","unstructured":"Centers for Disease Control and Prevention. New ICD-10-CM code for post-COVID conditions, following the 2019 novel coronavirus (COVID-19). Accessed September 1, 2022. https:\/\/www.cdc.gov\/nchs\/data\/icd\/announcement-new-icd-code-for-post-covid-condition-april-2022-final.pdf"},{"key":"zoi221000r7","unstructured":"Centers for Disease Control and Prevention. ICD-10-CM tabular list of diseases: U09.9. 2022. Accessed September 1, 2022. https:\/\/icd10cmtool.cdc.gov\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2797042\/mcgrath_2022_oi_221000_1664303844.06128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T15:40:17Z","timestamp":1665070817000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2797042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.35089","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]}}}